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that adjunctive treatment with aripiprazole provides health beneﬁts compared to 
quetiapine and olanzapine in patients with MDD that fail to respond to conventional 
antidepressants. With country speciﬁc cost-data, this model is also suited to assess the 
cost-effectiveness of different adjunctive strategies in MDD in different countries.
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OBJECTIVES: To compare injectable and oral atypical antipsychotics in reducing 
relapses in adult schizophrenia patients. METHODS: A systematic review of literature 
was conducted in MEDLINE and EMBASE (January 1995-August 2009) to identify 
randomized controlled trials and comparative open-label studies of atypical antipsy-
chotics performed on adult schizophrenia outpatients. Proceedings of the American 
Psychiatric Association Conference from 2006 to 2009 and bibliographies of identiﬁed 
studies and relevant reviews were also searched. Included studies had to have a clear 
deﬁnition of relapse (e.g. hospitalization or return to symptomatic condition), and a 
minimum follow-up period of 6 months. Comparators included atypical antipsychot-
ics, typical antipsychotics, or placebo. Data extraction was validated by a second 
reviewer. A Bayesian mixed treatment comparison (MTC), enabling indirect compari-
sons of interventions while respecting randomization, was performed on the rate of 
relapse assuming random study effects. RESULTS: Ten articles were identiﬁed and 
included in the systematic review and MTC. The odds ratio (OR) [95% credible 
interval (CI)] of relapse relative to placebo ranged from 0.13 [0.04, 0.47] (oral 
risperidone) to 0.20 [0.03, 1.19] (aripiprazole) among oral atypical agents, and 0.29 
[0.07, 1.12] for typical agent haloperidol. The OR [95% CI] of relapse of injectible 
risperidone relative to oral formulations of atypicals ranged from 0.28 [0.05, 1.24] 
(aripiprazole) to 0.41 [0.12, 1.01] (olanzapine). Injectable risperidone had lower odds 
of relapse than oral risperidone, olanzapine, quetiapine, aripiprazole, combination 
therapy, haloperidol, and placebo with probabilities > 95% and quetiapine XR, clo-
zapine, and ziprasidone with probabilities of 85%, 90%, and 93%, respectively. 
Findings were robust to varying trial durations and responder deﬁnitions. CONCLU-
SIONS: Oral formulations of various atypical antipsychotics, as well as typical halo-
peridol, offer similar beneﬁts over placebo in reducing relapse rates. Statistical and 
clinically important differences in relapse rates exist between oral and injectable for-
mulations of atypicals in favor of injectable risperidone.
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OBJECTIVES: There are four FDA-approved alcoholism medications: disulﬁram, 
naltrexone, acamprosate, and extended-release naltrexone (XR-NTX). This study used 
observational data to evaluate the utilization and cost outcomes of insured patients 
treated with alcohol medications or no medication. METHODS: Data were from 
Thomson Reuter’s MarketScan Commercial insurance claims database which contains 
information from millions of enrollees annually. Outcomes were measured six months 
after index and included medication possession ratio (MPR), detoxiﬁcation admissions 
and days, alcohol-related admissions and days, ED visits, psychiatric and substance 
abuse outpatient visits and charges for detoxiﬁcation and alcohol-related inpatient 
stays. Two sets of analyses were conducted: 1) Persons with an alcohol use disorder 
and no use of any alcohol medication (n = 4,047) were compared to persons with an 
alcohol use disorder and use of any of the four medications (n = 4,730). The samples 
were propensity-score matched on demographics, clinical characteristics and prior use 
of alcohol and psychiatric services, and 2) The four medications were compared 
(XR-NTX n = 275; naltrexone n = 2064 acamprosate n = 5068; disulﬁram n = 2076) 
using inverse probability weighting. RESULTS: The probability of any detoxiﬁcation 
admission, alcohol-related admission, and ED visit and a substance abuse or psychi-
atric visit was signiﬁcantly higher among no medication users than medications users. 
XR-naltrexone users had a signiﬁcantly higher MPR than acamprosate users. Patients 
using any medication had fewer detoxiﬁcation days and alcoholism-related inpatient 
days. Among medication users, XR-NTX was associated with signiﬁcantly lower 
detoxiﬁcation costs (per 1000 patients over 6 months) versus oral naltrexone, disul-
ﬁram and acamprosate (Detox: $0.60-million vs. $1.48-million, $1.08-million, $1.40-
million; respectively; P < 0.01 for XR-NTX vs. naltrexone and acamprosate). 
CONCLUSIONS: Individuals receiving alcoholism medications had signiﬁcantly and 
substantially lower detoxiﬁcation and hospitalization utilization rates than similar 
patients who received no medication. Of the approved medications, XR-TX had lower 
costs for detoxiﬁcation and alcoholism hospitalization days.
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OBJECTIVES: Treatment discontinuation has been increasingly used as a quantiﬁable 
tool for measuring the overall effectiveness of antipsychotic medications, including 
efﬁcacy, safety, and tolerability of a drug. While results have been inconsistent, several 
studies have found that olanzapine and other second-generation antipsychotics (SGA) 
are more effective in the treatment of schizophrenia compared to ﬁrst-generation 
antipsychotics (FGA). This meta-analysis compared time to and rate of treatment 
discontinuation of antipsychotics in schizophrenia. METHODS: Electronic search 
strategies identiﬁed all relevant papers on the topic published up to April 2009. 
Randomized controlled trials (RCTs) and observational studies that compared olan-
zapine with SGAs and/or FGAs for patients with schizophrenia were included in the 
meta-analyses. Hazard ratios (HR), Relative Risks (RR) and their associated 95% 
conﬁdence intervals (CIs) were extracted. RESULTS: There were 60 RCTs (N = 
33,360) and 27 observational studies (N = 202,591) included. The meta-analysis of 
time to discontinuation revealed that olanzapine was signiﬁcantly better as compared 
to aripiprazole, quetiapine, risperidone, ziprasidone, and perphenazine within ran-
domized trials and better than amisulpride, risperidone, haloperidol, and perphenazine 
within observational studies. Discontinuation rates in the RCTs were signiﬁcantly 
lower for olanzapine compared to all antipsychotics except for clozapine. In the 
observational studies, olanzapine was more effective than amisulpride and haloperi-
dol, and less effective than clozapine. Subgroup analysis indicated that industry spon-
sorship (Lilly vs. other sources) and olanzapine dosages did not affect the results, 
except for observational studies published by companies other than Lilly which found 
olanzapine to be more favorable compared to FGAs). CONCLUSIONS: In both 
randomized trials and observational studies, time to and rates of discontinuation, 
which are overall indices of effectiveness, olanzapine was better than most SGAs and 
FGAs, except for clozapine.
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OBJECTIVES: This study aimed to identify schizophrenia patients who experience 
favorable outcomes over a 3-year period and determine baseline predictors of favor-
able long-term outcomes. METHODS: We used data of a 3-year prospective, obser-
vational study of individuals treated for schizophrenia in the United States (US-SCAP; 
N = 2327). A hierarchical cluster analysis was performed to group patients, using 
baseline clinical, functional, and resource utilization measures. Clinical status was 
based on symptom severity. Functional level reﬂected patient-reported productivity 
and occupational role functioning. Resource utilization of psychiatric hospitalization 
and emergency services was systematically abstracted from medical records. A patient 
was classiﬁed as having a favorable long term outcome if their outcome values had 
the closest distance to the deﬁned “best baseline cluster” at each point over the 3-year 
follow-up; stepwise logistic regression was used to determine baseline predictors. 
RESULTS: Of 1604 patients with sufﬁcient data to assess 3-year outcomes, only 191 
(12%) experienced favorable outcomes. Overall, 5 distinct outcome clusters were 
identiﬁed, ranging from best to worst. The baseline predictors of the most favorable 
outcomes sustained over the 3-year period included better quality of life, more daily 
activities, patient-reported clearer thinking, less severe positive symptoms, lower AIMS 
score, higher level of global functioning, being employed, not having health insurance, 
being female, and not having help with shopping, leisure, or social activities. CON-
CLUSIONS: This study identiﬁed 5 distinct clusters of patients with schizophrenia 
based on their baseline clinical, functional, and resource utilization factors. Current 
ﬁndings suggest that clinicians could make early projections of long-term outcome, 
thus enabling early tailored therapeutic interventions that could enhance patient’s 
likelihood of achieving more favorable long-term outcomes.
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OBJECTIVES: Augmentation with atypical antipsychotics are effective in treating 
patients suffering from major depressive disorder (MDD) and that respond insufﬁ-
ciently to conventional antidepressants. Direct head-to-head trials comparing these 
agents are lacking. An indirect comparison was conducted to assess the comparative 
efﬁcacy and safety of augmentation with atypical antipsychotics in MDD. METHODS: 
A systematic literature search was conducted of Medline/PubMed (1966-September 
2009). Eligible trials enrolled patients diagnosed with unipolar major depressive dis-
order with resistance to at least one prior antidepressant. Trials had to be double-blind 
placebo controlled assessing the efﬁcacy and/or safety of augmentation therapy with 
aripiprazole, quetiapine, or olanzapine during an acute depressive episode. Response 
